Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.

Inclusion Criteria:

• Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
• Locally progressed or distant metastatic unresectable advanced HCC
• Progressed after second-line therapy
• Agree to participate in the study and sign the informed consent form

Exclusion Criteria:

• Not suitable for ablation surgery
• Pregnant, lactating and planning to become pregnant
• Orthostatic hypotension
• Mixed liver cancer
• Intestinal obstruction
• Obvious bleeding tendencies and hematologic diseases
• Acute or severe systemic infection;
• Stroke or transient ischemic attack (TIA) within two weeks;
• Acute coronary syndrome within two weeks;
• Evaluated to be not suitable for this trial by investigators